TheU.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for Simparica TRIO (sarolaner, moxidectin, and pyrantel chewable tablets) to treat New World screwworm (NWS) infestations (myiasis) in dogs and puppies. New World screwworm (NWS) larvae cause severe, often fatal damage by burrowing into the flesh of livestock, pets, wildlife, birds, and even humans. Photo courtesy USDA APHIS According to the agency, most U.S. dogs currently face low exposure risk based on geography. However, dogs living in, traveling to, or returning from areas where NWS has been identified should be monitored for signs including visible maggots or foul odors from wounds or body openings. Immediate veterinary care is recommended for suspected infestations. NWS has currently been detected in specific areas of Texas and New Mexico. “The FDA continues to authorize products to give veterinarians and pet owners multiple treatment options, in the unlikely event animals under their care become infested with New World screwworm,” says Acting FDA commissioner Kyle Diamantas, J.D. “To date, the U.S. has been successful in containing the spread of NWS. We are hopeful it will remain that way, and by authorizing products like this, the U.S. will be ready if the need arises.” The FDA says that, based on the available scientific evidence, Simparica TRIO may be effective for treating NWS myiasis in dogs and puppies when used as authorized, and that its potential benefits outweigh its known and potential risks. However, it is not authorized to prevent NWS. “We want dog owners to be informed, not alarmed,” says Timothy Schell, PhD, director of the FDA's Center for Veterinary Medicine. “The best thing dog owners can do right now is stay aware of the situation, know the signs of infestation, and have a conversation with their veterinarian if they have concerns.” For more information, visit the FDA websiteFDA website.
